Most Read Articles
10 Jan 2018
Shared decision support with the use of standardized decision aids improves decision quality and reduces implantation of left ventricular assist device as destination therapy (DT-LVAD) in patients with advanced heart failure.
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
10 Jan 2018

A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.

Pearl Toh, 15 Dec 2017
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.

Repeated yearly exposure to exercise training improves BP, MetS evolution

19 Sep 2017

There is a need for at least 2 consecutive years of 4-month aerobic interval training to chronically enhance metabolic syndrome (MetS; z score), a recent study has found. Blood pressure (BP) that does not fully revert to pretraining values mediates this chronic effect, allowing a cumulative improvement.

“On the other hand, sedentarism in MetS patients during 3 years increases their predicted atherosclerotic diseases risk,” researchers said.

In this study that sought to determine whether repeated yearly training programmes consolidate the transient BP improvements of one exercise programme into durable adaptations, obese middle-age individuals with MetS went through high-intensity aerobic interval training during 16 weeks in 3 consecutive years (training group [TRAIN]; n=23).

Researchers then compared the evolution of MetS components with a matched-group that remained sedentary (control group [CONT]; n=26).

TRAIN reduced systolic arterial pressure (‒8.5±2.5 mm Hg), blood glucose (‒19.9±2.6 mg/dl), waist circumference (‒3.8±0.1 cm) and MetS z score (‒0.3±0.1) below CONT (p<0.05 for all) at the end of the first training programme (0 to 4 months). With detraining (month 4 to 12) TRAIN adaptations returned to baseline levels (month 0) except for BP.

After the second exercise programme (month 12 to 16), TRAIN lowered blood glucose (‒19.0±2.0 mg/dl) and waist circumference (‒4.1±0.1 cm) below CONT. Blood glucose, BP and z score started below CONT values after detraining (‒6.8±0.9 mm Hg; ‒24.6±2.5 mg/dl and ‒0.4±0.05, respectively; p<0.05 for all). These differences grew wider with the last training programme (month 24 to 28).

Only in CONT did the 10-year risk estimation of atherosclerotic cardiovascular disease increased (8.6±1.1 to 10.1±1.3 percent; year 2 to 3; p<0.05).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
10 Jan 2018
Shared decision support with the use of standardized decision aids improves decision quality and reduces implantation of left ventricular assist device as destination therapy (DT-LVAD) in patients with advanced heart failure.
21 Dec 2017
Physicians’ practice patterns in managing hypertension, and their awareness of blood pressure variability, were reported in a recent study in Singapore. We discussed some of the clinical practice gaps identified by this study with author, A/Prof. Teo Boon Wee.
10 Jan 2018

A new batch of apolipoprotein B (apoB)-lowering drugs that capitalize on statins’ ability to lower lipids will further benefit patients at high cardiovascular (CV) risk who need to be treated more aggressively.

Pearl Toh, 15 Dec 2017
Blood pressure (BP) readings appeared to be similar regardless of whether BP measurements were attended or unattended by staff, nor were CV outcomes different between the two techniques, according to a post hoc survey on participants following the SPRINT* trial.